Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors-Reference-Cited by-同舟云学术

Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors

Published:2019-12 Issue:8 Volume:30 Page:385-392
ISSN:0957-5235
Container-title:Blood Coagulation & Fibrinolysis
language:en
Short-container-title:

Author:

Shirayama Rie,Takedani Hideyuki,Chikasawa Yushi,Ishiguro Akira,Ishimura Masataka,Isobe Kiyotaka,Uchiba Mitsuhiro,Ogata Yoshiyasu,Kakuda Harumi,Kusuhara Koichi,Shirahata Akira

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology,General Medicine

Reference20 articles.

1. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review;Kraut;Haemophilia,2007

2. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors;Giangrande;Haemophilia,2009

3. Experience of four UK comprehensive care centres using FEIBA for surgeries in patients with inhibitors;Rangarajan;Haemophilia,2011

4. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies;Négrier;Haemophilia,2013

5. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors;Lauroua;Haemophilia,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture;Annals of Hematology;2024-04-13

2. Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot^®) evaluated by global coagulation assay in patients with acquired haemophilia A;Haemophilia;2023-11-29

3. The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A;Blood Coagulation & Fibrinolysis;2023-07-19

4. Factor VIIa/factor X製剤と高用量recombinant factor VIIa製剤の併用療法を施行した血友病Bインヒビター1症例の凝固能評価;Japanese Journal of Thrombosis and Hemostasis;2023

5. 血友病インヒビター治療薬factor VIIa/factor X製剤の現状と展望;Japanese Journal of Thrombosis and Hemostasis;2023